ReviewPediatric nephrology (Berlin, Germany)2026
Nephrotoxicity of immunotherapy and targeted therapies used to treat paediatric cancer.
Review in Pediatric nephrology (Berlin, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
- Behavioral and Psychological Financial Hardship Among Caregivers of Pediatric Cancer Patients.Cancer medicine · 2026Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Children with cancer have had significant improvements in cure rates over the last few decades through advancements in surgery, chemotherapy, and radiation therapy. However, survivors have been left with long-term adverse effects of therapy, including significant nephrotoxicity. With advancement in genomic sequencing and novel therapeutics, there has been a recent shift towards the incorporation of targeted therapies and immunotherapy to improve cure rates and reduce long-term sequelae in survivors. However, these new therapies are not without their own toxicities, and with more widespread use of these agents, paediatric oncologists and nephrologists need to be aware of the short- and long-term impact of these treatments on children with cancer. This review highlights some of the emerging knowledge regarding the impact of these novel therapeutics on the kidneys.
Indexed as
Identifiers
40622576What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.